• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Neurocrine Biosciences Inc. (Amendment)

    2/14/22 2:34:19 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NBIX alert in real time by email
    SC 13G/A 1 nbix13gadec21.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) NEUROCRINE BIOSCIENCES INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 64125C109 (CUSIP NUMBER) December 31, 2021 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 1,568,056 6. Shared Voting Power* 0 7. Sole Dispositive Power* 4,359,645 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 4,359,645 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 4.5% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: NEUROCRINE BIOSCIENCES INC Item 1(b) Address of Issuer's Principal Executive Offices: 12780 EL CAMINO REAL, SAN DIEGO, CALIFORNIA 92130 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. ("Price Associates") Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 64125C109 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class This statement is being filed to report the fact that, as of the date of this report, the reporting person(s) has (have) ceased to be the beneficial owner of more than five percent of the class of securities. Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: February 14, 2022 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 12/31/2021
    Get the next $NBIX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NBIX

    DatePrice TargetRatingAnalyst
    7/21/2025$163.00Buy
    Truist
    7/10/2025$182.00Buy
    Goldman
    4/15/2025$138.00Hold → Buy
    Needham
    4/14/2025$137.00Sector Perform → Outperform
    RBC Capital Mkts
    2/11/2025$138.00Hold
    Deutsche Bank
    10/10/2024$155.00Outperform
    Raymond James
    8/29/2024$131.00 → $159.00Neutral → Overweight
    Piper Sandler
    4/24/2024$140.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $NBIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Regulatory Officer Delaet Ingrid exercised 457 shares at a strike of $79.02 and sold $61,695 worth of shares (457 units at $135.00) (SEC Form 4)

      4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      7/11/25 5:15:12 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Onyia Jude exercised 59,819 shares at a strike of $84.74 and sold $7,803,688 worth of shares (59,819 units at $130.46) (SEC Form 4)

      4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      7/11/25 5:01:03 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Onyia Jude sold $2,649,738 worth of shares (20,362 units at $130.13) and exercised 20,362 shares at a strike of $84.74 (SEC Form 4)

      4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      7/7/25 4:10:27 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition

      Technology-enabled research approach and AI-powered analysis identify unmet needs in patients with congenital adrenal hyperplasia SAN FRANCISCO, July 15, 2025 /PRNewswire/ -- PicnicHealth, a health technology company dedicated to advancing the next generation of non-interventional research, today announced its research collaboration with Neurocrine Biosciences, Inc. (NASDAQ:NBIX), the CAHtalog® Registry, identified an unmet need in patients with classic congenital adrenal hyperplasia (CAH). Using PicnicHealth's AI-powered technology to curate medical records and enable remote participation, the study revealed that CAH patients require lifelong, continuous adjustments to glucocorticoid dosing

      7/15/25 9:00:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025

      Approximately 95% of adult and pediatric patients were exposed to supraphysiologic doses of glucocorticoids and/or experienced elevated androstenedione levels at least once during their treatment journeyReal-world findings underscore long-term challenges of managing classic congenital adrenal hyperplasia and highlight clinical need for therapies to reduce androgen excess without high glucocorticoid dosesSAN DIEGO, July 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced results from a new analysis using real-world data from CAHtalog®, a comprehensive registry of patients with classic congenital adrenal hyperplasia in the United States. The analysis demonstrate

      7/15/25 8:30:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting

      Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clinically meaningful weight reductionsSubstantial improvements in insulin resistance were also observed in both adult and pediatric patients treated with CRENESSITY compared with placebo through one year of treatmentSAN DIEGO, July 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the presentation of new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies showing favorable trends in improvement of weight-related outcomes in patients with classic congenital adrenal hyperplasia who were treated with CRENESSITY® (crinecerfont) for

      7/14/25 4:35:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Neurocrine Biosciences with a new price target

      Truist initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $163.00

      7/21/25 8:37:42 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman initiated coverage on Neurocrine Biosciences with a new price target

      Goldman initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $182.00

      7/10/25 8:58:47 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences upgraded by Needham with a new price target

      Needham upgraded Neurocrine Biosciences from Hold to Buy and set a new price target of $138.00

      4/15/25 7:52:35 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 13, 2024 - FDA Approves New Treatment for Congenital Adrenal Hyperplasia

      For Immediate Release: December 13, 2024 Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).“Today’s approval provides an important advance for patients with classic con

      12/13/24 5:54:17 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    SEC Filings

    See more
    • Neurocrine Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/30/25 4:05:10 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/22/25 4:03:59 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Neurocrine Biosciences Inc.

      S-8 POS - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/21/25 5:28:04 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    Leadership Updates

    Live Leadership Updates

    See more
    • Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

      SAN DIEGO, June 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, an accomplished leader with 25 years of experience in information technology and artificial intelligence, will be responsible for driving the vision and long-term strategic direction of the company's technology initiatives. "Lewis is a proven global healthcare leader with a track record of utilizing technology to drive both cultural and technological change," said Matt Abernethy, Chief Finan

      6/9/25 4:05:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

      SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment. "Mr. Aberne

      5/30/25 4:30:14 PM ET
      $FATE
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

      Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO, April 4, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswani, an accomplished physician-scientist who has more than 20 years of pharmaceutical industry experience with broad R&D expertise in multiple therapeutic areas, will lead the clinical development and medical affairs activities at Neurocrine. Dr. Keswani succeeds Eiry W. Roberts, M.D., who has served as C

      4/4/25 8:00:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    Financials

    Live finance-specific insights

    See more
    • Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results

      Conference Call and Webcast Scheduled for Wednesday, July 30 SAN DIEGO, July 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its second quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2025. The schedule for the press release and conference call / webcast is as follows: Q2 2025 Press Release: July 30, 2025 at 1:00 p.m. PT / 4:00 p.m. ETQ2 2025 Conference Call: July 30, 2025 at 1:30 p.m. PT / 4:30 p.m. ETDomestic Dial-In Number: 800-225-9448Internat

      7/9/25 4:01:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance

      INGREZZA® (valbenazine) First-Quarter 2025 Net Product Sales of $545 Million and Reaffirms 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont) First-Quarter 2025 Net Product Sales of $14.5 Million with 413 Total Patient Enrollment Start Forms Initiated Phase 3 Registrational Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia to Position for Next Phase of Growth SAN DIEGO, May 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the first quarter ended March 31, 2025, and reaffirms its 2025 financial guidance.

      5/5/25 4:01:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results

      Conference Call and Webcast Scheduled for Monday, May 5 SAN DIEGO, April 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its first quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on May 5, 2025. The schedule for the press release and conference call / webcast is as follows: Q1 2025 Press Release: May 5, 2025 at 1:00 p.m. PT / 4:00 p.m. ETQ1 2025 Conference Call: May 5, 2025 at 1:30 p.m. PT / 4:30 p.m. ETDomestic Dial-In Number: 800-245-3047International Dial

      4/14/25 4:01:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Neurocrine Biosciences Inc.

      SC 13G - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

      10/17/24 9:54:01 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Neurocrine Biosciences Inc. (Amendment)

      SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

      2/9/23 11:27:44 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Neurocrine Biosciences Inc. (Amendment)

      SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

      2/14/22 2:34:19 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care